Vasculitis & polymyalgia rheumatica
What is a response in randomised controlled trials in giant cell arteritis?
Main finding
As reported in the abstract
- Previous randomised controlled trials (RCTs) in giant cell arteritis (GCA) applied different primary endpoints, limiting comparison of treatment effects in meta-analyses and creating heterogeneity of outcomes
- Change of disease activity is a fundamental component of response; whether GC tapering and/or maintenance of a disease state for a specific period should be part of response assessment is debatable
- Imaging and novel laboratory biomarkers as possible objective markers of disease activity need further investigation, possibly where drugs influence ESR and CRP
- Future response criteria might be a multidomain set; domains and their relative weights remain to be defined
Original publication
What is a response in randomised controlled trials in giant cell arteritis? Ann Rheum Dis. Published 17 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →